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LB 11058 is a novel parenteral cephalosporin with a C-3 pyrimidinyl-substituted vinyl sulfide group and a
C-7 2-amino-5-chloro-1,3-thiazole group. This study evaluated the in vitro activity and spectrum of LB 11058
against 1,245 recent clinical isolates, including a subset of gram-positive strains with specific resistant
phenotypes. LB 11058 was very active against Streptococcus pneumoniae. The novel cephalosporin was 8- to
16-fold more potent than ceftriaxone, cefepime, or amoxicillin-clavulanate against both penicillin-intermediate
and -resistant S. pneumoniae. LB 11058 was also very active against both -hemolytic streptococci (MIC at
which 90% of isolates were inhibited [MIC90], <0.008 g/ml) and viridans group streptococci (MIC90, 0.03 to
0.5 g/ml), including penicillin-resistant strains. Among oxacillin-susceptible Staphylococcus aureus, LB 11058
MIC results varied from 0.06 to 0.25 g/ml (MIC50, 0.12 g/ml), while among oxacillin-resistant strains LB
11058 MICs varied from 0.25 to 1 g/ml (MIC50, 1 g/ml). Coagulase-negative staphylococci showed an LB
11058 susceptibility pattern similar to that of S. aureus, with all isolates being inhibited at<1 g/ml. LB 11058
also showed reasonable in vitro activity against Enterococcus faecalis, including vancomycin-resistant strains
(MIC50, 1 g/ml), and Bacillus spp. (MIC50, 0.25 g/ml); however, it was less active against Enterococcus
faecium (MIC50, >64 g/ml) and Corynebacterium spp. (MIC50, 32 g/ml). Against gram-negative pathogens,
LB 11058 showed activity against Haemophilus influenzae (MIC90, 0.25 to 0.5 g/ml) and Moraxella catarrhalis
(MIC90, 0.25 g/ml), with MICs not influenced by -lactamase production. In conclusion, LB 11058 demon-
strated a broad antibacterial spectrum and was highly active against gram-positive bacteria, particularly
against multidrug-resistant staphylococci and streptococci.
Gram-positive bacterial pathogens have shown a remarkable
ability to develop resistance to antimicrobial agents. Oxacillin-
and glycopeptide-resistant staphylococci, glycopeptide-resis-
tant enterococci, and penicillin-resistant Streptococcus pneu-
moniae and viridans streptococci have forced clinicians to seek
alternative treatments for patients with serious gram-positive
infections (1, 2, 3, 11, 15, 16).
Oxacillin-resistant Staphylococcus aureus (MRSA) repre-
sents an important worldwide problem, and its prevalence may
vary significantly from hospital to hospital. Data from the
global SENTRY Antimicrobial Surveillance Program and
other surveillance programs revealed a high and increasing
prevalence of this pathogen in the United States, Latin Amer-
ica, and several regions of Europe (5; European Antimicrobial
Resistance Surveillance System [http://www.earss.rivm.nl], ac-
cessed 24 September 2003). Over the past few years, MRSA
has acquired stable resistance to most clinically available anti-
microbial agents, and therapeutic options have been limited to
the glycopeptides (vancomycin and teicoplanin) and, more re-
cently, quinupristin-dalfopristin and linezolid (4, 7). However,
clinical isolates with reduced susceptibilities to these latter
compounds have recently been described in several regions of
the world (5, 7, 13). Most MRSA isolates show resistance to
virtually all -lactams by production of penicillinase and a
low-affinity penicillin-binding protein (PBP) called PBP 2a.
-Lactams with relatively high affinities for PBP 2a, such as
penicillin, ampicillin, and amoxicillin, combined with -lacta-
mase inhibitors have demonstrated in vitro and in vivo anti-
MRSA activities (10). However, the addition of critical
amounts of -lactamase inhibitor are necessary to successfully
treat these infections. Thus, -lactams must combine both high
affinity for PBP 2a and stability against degradation by staph-
ylococci penicillinase to be considered for clinical use against
infections caused by this pathogen (2, 12).
S. pneumoniae is the most commonly identified bacterial
cause of community-acquired pneumonia, otitis media, and
meningitis, and it is a frequent pathogen in bacteremia (6, 21).
Morbidity and mortality may be high among patients with
bacteremia and meningitis, especially when appropriate anti-
microbial therapy is delayed. The emergence of S. pneumoniae
with antimicrobial resistance has also become a matter of ma-
jor concern. Resistance to penicillin and other antimicrobial
agents has increased significantly in the last decade, making the
treatment of serious infections very difficult, especially among
children (15, 16, 19, 20, 22).
LB 11058 is a novel parenteral cephalosporin with a C-3
pyrimidinyl-substituted vinyl sulfide group and a C-7 2-amino-
5-chloro-1,3-thiazole group (Fig. 1). Preliminary studies have
indicated that this compound has potent in vitro activity
against gram-positive bacteria, including multidrug-resistant
staphylococci and streptococci. This study was designed to
confirm and extend the earlier presentations about the potency
and spectrum of LB 11058 (Y. Cho, M. Kim, C. S. Lee, and H.
Youn, 42nd Intersci. Conf. Antimicrob. Agents Chemother.,
abstr. F-330, 2002; H. Joo, J. E. Shin, I. H. Choi, D. H. Park,
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MATERIALS AND METHODS
Antimicrobials tested. The LB 11058 reagent-grade compound was provided
by LG Life Science, Ltd. (Taejon, South Korea). Comparator agents were pur-
chased from Sigma Chemical Co. (St. Louis, Mo.) or obtained from their re-
spective manufacturers in the United States. A total of 31 comparators were
evaluated, depending upon the species tested. These compounds included -lac-
tams (penicillins, cephalosporins, penicillin–-lactamase inhibitor combinations,
a monobactam, and a carbapenem), fluoroquinolones, aminoglycosides, tri-
methoprim-sulfamethoxazole, and several gram-positive-focused agents (macro-
lide-lincosamide-streptogramins, glycopeptides, and oxazolidinones).
Organisms tested. A total of 1,245 well-characterized strains derived from
numerous laboratories worldwide, including a subset of gram-positive strains
with specific resistant phenotypes, were processed in the study. Only nondupli-
cate isolates judged to be clinically significant by local criteria were included in
the study. All isolates were collected in 2002, except some isolates of the multi-
drug-resistant subset. The collection of organisms included 102 isolates of -he-
molytic streptococci, 205 S. pneumoniae isolates (103 penicillin nonsusceptible),
106 isolates of viridans group streptococci (54 penicillin nonsusceptible), 163 S.
aureus isolates (110 MRSA), 101 coagulase-negative staphylococci (CoNS; 76
oxacillin resistant), 64 Enterococcus faecalis isolates (20 vancomycin resistant), 63
Enterococcus faecium isolates (33 vancomycin resistant), 17 Enterococcus spp.
isolates, 20 Bacillus spp. isolates, 20 Corynebacterium spp., 203 Haemophilus
influenzae isolates (101 -lactamase positive), 102 Moraxella catarrhalis isolates,
31 Enterobacteriaceae isolates, and 12 isolates of nonfermentative gram-negative
bacilli. The subsets of multidrug-resistant gram-positive strains included six
staphylococci with elevated vancomycin MICs (vancomycin-intermediate or -re-
sistant staphylococci), 10 linezolid-nonsusceptible strains, and 20 quinupristin-
dalfopristin (Synercid)-nonsusceptible strains.
Susceptibility testing methods. LB 11058 MICs were determined by the ref-
erence methods according to procedures recommended by the National Com-
mittee for Clinical Laboratory Standards (NCCLS) (17, 18). On each day of
testing, a fresh stock solution (1,280 g/ml) of LB 11058 was prepared and then
serially diluted for a testing concentration range of 0.008 to 64 g/ml. Supple-
mented 5% lysed horse blood was added for testing Streptococcus spp. and
Corynebacterium spp., and Haemophilus test medium was utilized for testing H.
influenzae. The MICs were interpreted according to NCCLS criteria (18). Quality
control was monitored using the following organisms: S. pneumoniae ATCC
49619, E. faecalis ATCC 29212, S. aureus ATCC 29213, Escherichia coli ATCC
25923, and Pseudomonas aeruginosa ATCC 27853.
RESULTS
The in vitro activities of LB 11058 in comparison to numer-
ous other antimicrobial agents against gram-positive bacteria
are summarized in Table 1. LB 11058 was very potent against
-hemolytic streptococci, with all strains being inhibited at
0.015 g/ml (MIC at which 90% of isolates were inhibited
[MIC90], 0.008 g/ml). LB 11058 was the most potent com-
pound tested against S. pneumoniae. Against S. pneumoniae,
LB 11058 activity varied according to the susceptibility to pen-
icillin. Penicillin-susceptible strains (MIC90, 0.008 g/ml)
were very susceptible to LB 11058, while penicillin-intermedi-
ate strains (MIC90, 0.06 g/ml) and penicillin-resistant strains
(MIC90, 0.12 g/ml) showed slightly higher LB 11058 MIC
results (0.06 to 0.25 g/ml). The novel cephalosporin was 8- to
16-fold more potent than ceftriaxone, cefepime, or amoxicillin-
clavulanate against both penicillin-intermediate and -resistant
strains. Penicillin-susceptible strains were very susceptible to
LB 11058 and most antimicrobial agents evaluated, except for
the macrolides (92.2 to 93.1% susceptible).
Similarly to S. pneumoniae, the susceptibilities of viridans
group streptococci to LB 11058 varied according to the peni-
cillin susceptibility. LB 11058 MICs ranged from 0.008 to
0.12 g/ml (MIC90, 0.03 g/ml) among penicillin-susceptible
isolates and from 0.03 to 1 g/ml (MIC90, 0.5 g/ml) among
penicillin-resistant strains. LB 11058 was also the most potent
compound tested against viridans group streptococci, being
16-fold more potent than ceftriaxone or cefepime against this
pathogen (Table 1).
LB 11058 showed potent in vitro activity against S. aureus,
including oxacillin-resistant strains. Among oxacillin-suscepti-
ble strains, LB 11058 MIC results varied from 0.06 to 0.25
g/ml (MIC90, 0.25 g/ml), while MRSA LB 11058 MICs rang-
ing from 0.25 to 1 g/ml (MIC90, 1 g/ml). LB 11058 (MIC50,
0.12 g/ml) was 32-fold more potent than ceftriaxone (MIC50,
4 g/ml), 16-fold more potent than cefepime (MIC50, 2 g/ml),
and 4-fold more potent than oxacillin (MIC50, 0.5 g/ml)
against oxacillin-susceptible isolates; only LB 11058 (MIC90, 1
g/ml), trimethoprim-sulfamethoxazole (MIC90, 1 g/ml),
vancomycin (MIC90, 2 g/ml), quinupristin-dalfopristin
(MIC90, 0.5 g/ml), and linezolid (MIC90, 2 g/ml) showed
reasonable in vitro activities against oxacillin-resistant strains.
CoNS showed an LB 11058 susceptibility pattern similar to
that shown by S. aureus, with all isolates being inhibited at 1
g/ml. LB 11058 (MIC90, 0.12 g/ml) was 32-fold more potent
than ceftriaxone (MIC90, 4 g/ml) and 16-fold more potent
than cefepime (MIC90, 2 g/ml) against oxacillin-susceptible
CoNS strains. It was also very active against oxacillin-resistant
strains (MIC90, 0.5 g/ml).
LB 11058 and ampicillin were the most active -lactams
evaluated against E. faecalis. Most E. faecalis isolates showed
LB 11058 MICs of 4 g/ml, except for one isolate which was
also resistant to linezolid and showed an LB 11058 MIC of64
g/ml. All other cephalosporins evaluated showed poor activ-
ity against this pathogen. In general, vancomycin-resistant E.
faecalis showed LB 11058 MIC results approximately fourfold
higher than vancomycin-susceptible E. faecalis (MIC50, 0.25
and 1 g/ml, respectively). The activity of LB 11058 was higher
against E. faecalis (MIC90, 2 g/ml) than against E. faecium
(MIC50, 64 g/ml). Most E. faecium strains showed high
MIC results for LB 11058 and most antimicrobial agents eval-
uated, except quinupristin-dalfopristin and linezolid.
LB 11058 (MIC50, 0.25 g/ml) and imipenem (MIC50, 0.12
g/ml) were the most potent -lactams tested against Bacillus
spp. (Table 1). The vast majority of Bacillus spp. isolates (85%)
had LB 11058 MICs of 0.5 g/ml. Several other compounds
showed reasonable activity against this pathogen, including
clindamycin (MIC50, 0.5 g/ml), levofloxacin (MIC50, 0.12 g/
ml), ciprofloxacin (MIC50, 0.12 g/ml), teicoplanin (MIC50,
0.12 g/ml), and quinupristin-dalfopristin (MIC50, 0.5 g/
ml). On the other hand, Corynebacterium spp. showed de-
FIG. 1. Chemical structure of LB 11058.
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TABLE 1. Antimicrobial activities of LB 11058 and selected comparison drugs tested against gram-positive species
Organism (no. tested) and antimicrobial agent
MIC (g/ml)
% Susceptible
50% 90% Range
-Hemolytic streptococci (102)
LB 11058 0.008 0.008 0.008–0.015 —a
Ceftriaxone 0.25 0.25 0.25 100
Cefepime 0.12 0.12 0.12–1 99
Penicillin 0.015 0.06 0.015–0.12 100
Amoxicillin-clavulanate 2 2 2 —
Erythromycin 0.06 2 0.06–8 82
Clindamycin 0.06 0.06 0.06–8 94
Chloramphenicol 2 4 2–4 100
Trimethoprim-sulfamethoxazole 0.5 0.5 0.5–2 —
Ciprofloxacin 0.5 1 0.25–4 —
Levofloxacin 0.5 1 0.12–2 100
Vancomycin 0.25 0.5 0.12–1 100
Quinupristin-dalfopristin 0.25 0.5 0.06–0.5 100
Linezolid 1 1 0.25–2 100
S. pneumoniae, penicillin susceptible (102)
LB 11058 0.008 0.008 0.008–0.06 —
Ceftriaxone 0.015 0.03 0.008–0.12 100
Cefepime 0.06 0.06 0.06–0.5 100
Penicillin 0.06 0.06 0.06–0.12 100
Amoxicillin-clavulanate 0.06 0.06 0.06 100
Erythromycin 0.25 0.25 0.25–16 93
Azithromycin 0.12 0.25 0.12–16 92
Clindamycin 0.06 0.06 0.06–0.5 100
Chloramphenicol 2 4 2–16 99
Ciprofloxacin 1 2 0.03–4 —
Levofloxacin 1 1 0.03–4 99
Trimethoprim-sulfamethoxazole 0.5 1 0.5–4 86
Vancomycin 0.25 0.5 0.06–1 100
Quinupristin-dalfopristin 0.5 0.5 0.06–0.5 100
Linezolid 0.5 1 0.25–2 100
S. pneumoniae, penicillin intermediate (52)
LB 11058 0.03 0.06 0.008–0.12 —
Ceftriaxone 0.25 0.5 0.015–2 98
Cefepime 0.25 1 0.06–4 98
Penicillin 0.25 1 0.12–1 0
Amoxicillin-clavulanate 0.25 1 0.06–2 100
Erythromycin 2 32 0.25–32 44
Azithromycin 2 16 0.12–16 46
Clindamycin 0.06 8 0.06–8 80
Chloramphenicol 4 4 2–16 92
Ciprofloxacin 1 2 0.25–4 —
Levofloxacin 1 1 0.25–4 98
Trimethoprim-sulfamethoxazole 0.5 2 0.5–2 50
Vancomycin 0.25 0.5 0.06–1 100
Quinupristin-dalfopristin 0.5 0.5 0.12–1 100
Linezolid 0.5 1 0.25–1 100
S. pneumoniae, penicillin resistant (51)
LB 11058 0.12 0.12 0.06–0.25 —
Ceftriaxone 1 1 0.03–8 92
Cefepime 1 2 0.5–2 84
Penicillin 2 4 2–4 0
Amoxicillin-clavulanate 2 8 1–8 65
Erythromycin 4 32 0.25–32 27
Azithromycin 4 16 2–16 26
Clindamycin 0.06 8 0.06–8 74
Chloramphenicol 4 16 2–16 83
Ciprofloxacin 1 2 0.5–4 —
Levofloxacin 1 1 0.5–4 94
Trimethoprim-sulfamethoxazole 2 2 0.5–2 17
Vancomycin 0.25 0.5 0.25–0.5 100
Quinupristin-dalfopristin 0.5 0.5 0.12–1 100
Linezolid 0.5 1 0.25–2 100
Continued on following page
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TABLE 1—Continued
Organism (no. tested) and antimicrobial agent
MIC (g/ml)
% Susceptible
50% 90% Range
Viridans group streptococci, penicillin susceptible (52)
LB 11058 0.015 0.03 0.008–0.12 —
Ceftriaxone 0.25 0.5 0.25–2 98
Cefepime 0.12 2 0.12–2 98
Penicillin 0.12 0.12 0.016–0.12 100
Amoxicillin-clavulanate 2 2 2 —
Erythromycin 0.06 4 0.06–8 71
Clindamycin 0.06 0.06 0.06–8 96
Chloramphenicol 2 4 2–8 98
Ciprofloxacin 1 4 0.25–4 —
Levofloxacin 1 2 0.25–4 94
Trimethoprim-sulfamethoxazole 0.5 0.5 0.5–2 —
Vancomycin 0.5 1 0.12–1 100
Quinupristin-dalfopristin 1 1 0.06–1 100
Linezolid 1 1 0.12–8 98
Viridans group streptococci, penicillin intermediate (27)
LB 11058 0.06 0.5 0.015–0.5 —
Ceftriaxone 0.5 2 0.25–2 70
Cefepime 0.5 2 0.12–4 82
Penicillin 1 2 0.015–2 0
Amoxicillin-clavulanate 2 4 2–16 —
Erythromycin 1 4 0.06–8 33
Clindamycin 0.06 1 0.06–8 85
Chloramphenicol 2 4 2–8 96
Ciprofloxacin 2 4 0.12–4 —
Levofloxacin 1 4 0.12–4 82
Trimethoprim-sulfamethoxazole 0.5 2 0.5–2 —
Vancomycin 0.5 0.5 0.25–1 100
Quinupristin-dalfopristin 0.5 1 0.25–2 96
Linezolid 1 1 0.25–2 100
Viridans group streptococci, penicillin resistant (27)
LB 11058 0.25 0.5 0.03–1 —
Ceftriaxone 4 32 1–32 4
Cefepime 4 16 4–16 19
Penicillin 4 32 4–32 0
Amoxicillin-clavulanate 8 16 4–16 —
Erythromycin 2 8 0.06–8 11
Clindamycin 0.06 8 0.06–8 78
Chloramphenicol 4 8 2–8 85
Ciprofloxacin 2 4 1–4 —
Levofloxacin 1 2 0.5–4 96
Trimethoprim-sulfamethoxazole 2 2 0.5–2 —
Vancomycin 0.5 1 0.25–1 100
Quinupristin-dalfopristin 0.5 1 0.25–4 89
Linezolid 1 1 0.5–2 100
S. aureus, oxacillin susceptible (53)
LB 11058 0.12 0.25 0.06–0.25 —
Ceftriaxone 4 4 0.5–32 98
Ceftazidime 8 8 4–16 91
Cefepime 2 4 0.5–16 98
Oxacillin 0.5 1 0.12–1 100
Amoxicillin-clavulanate 2 2 2–8 98
Erythromycin 0.5 8 0.25–8 70
Clindamycin 0.12 8 0.06–8 87
Ciprofloxacin 0.5 4 0.12–4 87
Levofloxacin 0.12 4 0.06–4 87
Trimethoprim-sulfamethoxazole 0.5 0.5 0.5–2 93
Vancomycin 1 1 0.5–2 100
Quinupristin-dalfopristin 0.25 0.5 0.12–1 100
Linezolid 2 2 1–2 100
S. aureus, oxacillin resistant (110)
LB 11058 1 1 0.25–1 —
Ceftriaxone 32 32 0.5–32 5
Ceftazidime 16 16 8–16 3
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TABLE 1—Continued
Organism (no. tested) and antimicrobial agent
MIC (g/ml)
% Susceptible
50% 90% Range
Cefepime 16 16 4–16 20
Oxacillin 8 8 8 0
Amoxicillin-clavulanate 16 16 2–16 6
Erythromycin 8 8 0.25–8 4
Clindamycin 8 8 0.12–8 19
Ciprofloxacin 4 4 0.24–4 6
Levofloxacin 4 4 0.12–4 7
Trimethoprim-sulfamethoxazole 0.5 1 0.5–2 90
Vancomycin 1 2 0.5–2 100
Quinupristin-dalfopristin 0.5 0.5 0.12–1 100
Linezolid 2 2 0.5–2 100
CoNS, oxacillin susceptible (25)
LB 11058 0.06 0.12 0.03–0.12 —
Ceftriaxone 2 4 1–8 100
Ceftazidime 4 8 2–16 100
Cefepime 0.5 2 0.25–4 100
Oxacillin 0.12 0.25 0.06–0.25 100
Amoxcillin-clavulanate 2 2 2 100
Erythromycin 0.25 8 0.12–8 64
Clindamycin 0.06 0.5 0.06–8 96
Ciprofloxacin 0.25 4 0.12–4 80
Levofloxacin 0.25 4 0.06–4 84
Trimethoprim-sulfamethoxazole 0.5 2 0.5–2 80
Vancomycin 1 2 0.5–2 100
Quinupristin-dalfopristin 0.12 0.5 0.06–0.5 100
Linezolid 1 1 0.25–2 100
CoNS, oxacillin resistant (76)
LB 11058 0.5 0.5 0.06–1 —
Ceftriaxone 16 32 0.25–32 28
Ceftazidime 16 16 2–16 7
Cefepime 8 16 0.12–16 71
Oxacillin 8 8 1–8 0
Amoxcillin-clavulanate 4 16 2–16 70
Erythromycin 8 8 0.06–8 9
Clindamycin 4 8 0.06–8 49
Ciprofloxacin 4 4 0.12–4 40
Levofloxacin 2 4 0.12–4 50
Trimethoprim-sulfamethoxazole 2 2 0.5–2 51
Vancomycin 2 2 0.5–2 100
Quinupristin-dalfopristin 0.25 0.5 0.06–1 100
Linezolid 1 1 0.5–2 100
Vancomycin-nonsusceptible staphylococci (6)b
LB 11058 0.5 1 0.25–1 —
E. faecalis, vancomycin susceptible (44)
LB 11058 0.25 1 0.12–64 —
Ceftriaxone 32 32 8–32 —
Cefepime 16 16 8–16 —
Ampicillin 2 2 2–4 100
Imipenem 2 2 0.5–4 —
Erythromycin 8 8 0.12–8 16
Chloramphenicol 8 8 4–16 89
Ciprofloxacin 4 4 0.5–4 —
Levofloxacin 1 4 0.5–4 61
Gentamicin (HL)c 500 1,000 500–1,000 80
Streptomycin (HL)c 1,000 2,000 1,000–2,000 80
Vancomycin 1 2 0.5–4 100
Teicoplanin 0.12 0.25 0.12–0.5 100
Quinupristin-dalfopristin 8 8 0.5–8 2
Linezolid 1 2 1–2 100
E. faecalis, vancomycin resistant (20)
LB 11058 1 4 0.25–4 —
Ceftriaxone 32 32 32 —
Cefepime 16 16 16–16 —
Ampicillin 2 8 2–16 90
Continued on following page
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TABLE 1—Continued
Organism (no. tested) and antimicrobial agent
MIC (g/ml)
% Susceptible
50% 90% Range
Imipenem 2 8 0.25–8 —
Erythromycin 8 8 8 100
Chloramphenicol 8 16 4–16 55
Ciprofloxacin 4 4 1–4 —
Levofloxacin 4 4 1–4 5
Gentamicin (HL)c 1,000 1,000 500–1,000 20
Streptomycin (HL)c 2,000 2,000 1,000–2,000 20
Vancomycin 16 16 16 0
Teicoplanin 16 16 0.12–16 30
Quinupristin-dalfopristin 8 8 4–8 0
Linezolid 1 2 1–2 100
E faecium, vancomycin susceptible (30)
LB 11058 64 64 0.5–64 —
Ceftriaxone 32 32 4–32 —
Cefepime 16 16 4–16 —
Ampicillin 16 16 2–16 21
Imipenem 8 8 1–8 —
Erythromycin 8 8 0.25–8 4
Chloramphenicol 8 8 4–16 92
Ciprofloxacin 4 4 1–4 —
Levofloxacin 4 4 2–4 21
Gentamicin (HL)c 500 1,000 500–1,000 79
Streptomycin (HL)c 1,000 2,000 1,000–2,000 52
Vancomycin 1 2 1–4 100
Teicoplanin 0.5 0.5 0.25–0.5 100
Quinupristin-dalfopristin 0.5 2 0.25–4 88
Linezolid 2 2 1–2 100
E. faecium, vancomycin resistant (33)
LB 11058 64 64 8–64 —
Ceftriaxone 32 32 32 —
Cefepime 16 16 16 —
Ampicillin 16 16 16 0
Imipenem 8 8 8 —
Erythromycin 8 8 2–8 0
Chloramphenicol 8 8 4–8 100
Ciprofloxacin 4 4 4 —
Levofloxacin 4 4 4 0
Gentamicin (HL)c 500 1,000 500–1,000 65
Streptomycin (HL)c 2,000 2,000 1,000–2,000 15
Vancomycin 16 16 16 0
Teicoplanin 16 16 0.25–16 12
Quinupristin-dalfopristin 0.5 1 0.25–2 96
Linezolid 2 2 1–4 96
Enterococcus spp. (17)
LB 11058 1 64 0.25–64 —
Ceftriaxone 32 32 1–32 —
Cefepime 16 16 1–16 —
Ampicillin 2 16 2–16 77
Imipenem 1 8 0.06–8 —
Erythromycin 2 8 0.06–8 29
Chloramphenicol 4 8 4–8 100
Ciprofloxacin 2 4 0.12–4 41
Levofloxacin 2 4 0.25–4 77
Gentamicin (HL)c 500 500 500–1,000 94
Streptomycin (HL)c 1,000 2,000 1,000–2,000 88
Vancomycin 4 16 0.25–16 71
Teicoplanin 0.5 16 0.12–16 88
Quinupristin-dalfopristin 2 4 0.25–4 24
Linezolid 2 2 1–2 100
Linezolid-resistant strains (10)d
LB 11058 0.5 64 0.008–64 —
Ceftriaxone 32 32 0.25–32 13
Cefepime 16 16 0.12–16 38
Ciprofloxacin 4 4 1–4 13
Vancomycin 2 16 0.5–16 63
Teicoplanin 0.5 16 0.12–16 75
Quinupristin-dalfopristin 0.5 8 0.25–8 88
Linezolid 8 8 8–8 0
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creased susceptibility to LB 11058 (MIC90, 64 g/ml) and
most antimicrobial agents evaluated, except for vancomycin
(MIC90, 0.5 g/ml), teicoplanin (MIC90, 1 g/ml), quinupris-
tin-dalfopristin (MIC90, 0.5 g/ml), and linezolid (MIC90, 0.5
g/ml).
Among the special subsets of isolates selected, all vancomy-
cin-nonsusceptible strains (MIC, 4 g/ml) were inhibited at
1 g of LB 11058/ml (Table 1). Also, linezolid resistance did
not affect LB 11058 activity among staphylococci and strepto-
cocci. All four linezolid-resistant staphylococcal isolates had an
TABLE 1—Continued
Organism (no. tested) and antimicrobial agent
MIC (g/ml)
% Susceptible
50% 90% Range
Trimethoprim-sulfamethoxazole 2 2 0.5–2 38
Quinupristin-dalfopristin-resistant strains (20)e
LB 11058 1 64 0.12–64 —
Ceftriaxone 32 32 8–32 15
Cefepime 16 16 2–16 15
Ciprofloxacin 4 4 1–4 15
Vancomycin 1 16 0.5–16 85
Teicoplanin 0.5 16 0.12–16 85
Quinupristin-dalfopristin 4 8 2–8 0
Linezolid 1 2 0.5–2 100
Trimethoprim-sulfamethoxazole 0.5 2 0.5–2 55
Bacillus spp. (20)f
LB 11058 0.25 4 0.03–4 —
Ceftriaxone 16 32 0.25–32 —
Cefepime 16 16 2–16 —
Penicillin 16 32 0.015–32 —
Ampicillin 16 16 2–16 —
Amoxicillin-clavulanate 8 16 2–16 —
Imipenem 0.12 2 0.06–8 —
Oxacillin 8 8 0.25–8 —
Erythromycin 0.25 1 0.06–8 —
Clindamycin 0.5 1 0.12–2 —
Chloramphenicol 2 4 2–4 —
Ciprofloxacin 0.12 0.25 0.06–0.5 —
Levofloxacin 0.12 0.25 0.06–0.5 —
Trimethoprim-sulfamethoxazole 1 2 0.5–2 —
Vancomycin 1 1 0.25–2 —
Teicoplanin 0.12 0.25 0.12–0.5 —
Quinupristin-dalfopristin 0.5 1 0.25–2 —
Linezolid 1 1 0.25–2 —
Corynebacterium spp. (20)g
LB 11058 32 64 0.06–64 —
Ceftriaxone 32 32 0.25–32 —
Cefepime 16 16 0.12–16 —
Penicillin 8 32 0.06–32 —
Amoxicillin-clavulanate 16 16 2–16 —
Imipenem 1 8 0.06–8 —
Oxacillin 8 8 1–8 —
Erythromycin 4 8 0.06–8 —
Clindamycin 8 8 0.12–8 —
Chloramphenicol 2 16 2–16 —
Ciprofloxacin 4 4 0.12–4 —
Levofloxacin 4 4 0.12–4 —
Trimethoprim-sulfamethoxazole 2 2 0.5–2 —
Vancomycin 0.5 0.5 0.12–0.5 —
Teicoplanin 0.5 1 0.12–1 —
Quinupristin-dalfopristin 0.12 0.5 0.06–2 —
Linezolid 0.25 0.5 0.25–0.5 —
a —, no interpretive criteria have been established by the NCCLS.
b Vancomycin-intermediate or -resistant staphylococci; includes S. aureus (four strains), S. epidermidis (one strain), and S. haemolyticus (one strain).
c High-level (HL) resistance.
d Includes E. faecium (four strains), E. faecalis (one strain), S. aureus (three strains), S. epidermidis (one strain), and S. oralis (one strain).
e Quinupristin-dalfopristin (Synercid)-resistant strains include E. faecium (nine strains), S. aureus (seven strains), S. epidermidis (two strains), and Staphylococcus spp.
(two strains).
f Includes Bacillus cereus (seven strains) and Bacillus spp. (13 strains).
g Includes Corynebacterium jeikeium (11 strains) and Corynebacterium spp. (nine strains).
VOL. 48, 2004 ACTIVITY OF LB 11058 59
TABLE 2. In vitro activities of LB 11058 and selected comparison drugs tested against gram-negative species
Organism (no. tested) and antimicrobial agent
MIC (g/ml)
% Susceptible
50% 90% Range
H. influenzae, -lactamase negative (102)
LB 11058 0.12 0.5 0.015–0.5 —a
Ceftriaxone 0.06 0.015 0.008–0.03 100
Cefepime 0.06 0.12 0.06–0.5 100
Ampicillin 0.5 1 0.5–1 100
Amoxicillin-clavulanate 0.5 1 0.06–2 100
Erythromycin 4 8 0.25–16 —
Azithromycin 1 2 0.12–4 100
Chloramphenicol 2 2 2 100
Ciprofloxacin 0.03 0.03 0.03 100
Levofloxacin 0.03 0.03 0.03 100
Trimethoprim-sulfamethoxazole 0.5 4 0.5–4 80
H. influenzae, -lactamase positive (101)
LB 11058 0.12 0.25 0.03–0.5 —
Ceftriaxone 0.008 0.008 0.008–0.015 100
Cefepime 0.06 0.25 0.06–0.25 100
Ampicillin 4 4 2–4 0
Amoxicillin-clavulanate 1 2 0.25–4 100
Erythromycin 4 8 0.5–16 —
Azithromycin 1 2 0.12–4 100
Chloramphenicol 2 2 2–16 96
Ciprofloxacin 0.03 0.03 0.03 100
Levofloxacin 0.03 0.03 0.03 100
Trimethoprim-sulfamethoxazole 0.5 4 0.5–4 96
M. catarrhalis (102)
LB 11058 0.03 0.25 0.008–0.5 —
Ceftriaxone 0.12 0.5 0.008–1 100
Cefepime 0.5 1 0.06–4 99
Ampicillin 1 4 0.5–4 58
Amoxicillin-clavulanate 0.12 0.25 0.06–0.5 100
Erythromycin 0.25 0.25 0.25–0.5 100
Azithromycin 0.12 0.12 0.12 100
Clarithromycin 0.25 0.25 0.25–0.5 100
Tetracycline 2 2 2 100
Chloramphenicol 2 2 2 100
Ciprofloxacin 0.03 0.06 0.03–0.06 100
Levofloxacin 0.03 0.06 0.03–0.06 100
Trimethoprim-sulfamethoxazole 0.5 0.5 0.5–1 99
Enterobacteriaceae (31)b
LB 11058 2 64 0.015–64 —
Ceftriaxone 0.25 0.25 0.25–32 87
Ceftazidime 1 1 1–16 81
Cefepime 0.12 0.12 0.12–4 100
Cefoxitin 16 32 2–32 44
Cefuroxime axetil 8 16 1–16 26
Cefazolin 16 16 2–16 32
Ampicillin 16 16 2–16 13
Amoxcillin-clavulanate 16 16 2–16 39
Piperacillin-tazobactam 2 16 0.5–64 90
Aztreonam 0.12 16 0.12–16 87
Imipenem 0.5 1 0.5–2 100
Amikacin 1 4 0.5–8 100
Gentamicin 2 2 2–8 94
Ciprofloxacin 0.03 4 0.03–4 81
Levofloxacin 0.06 4 0.03–4 81
Trimethoprim-sulfamethoxazole 0.5 2 0.5–2 77
Nonfermentative gram-negative bacilli (12)c
LB 11058 8 64 2–64 —
Ceftriaxone 32 32 8–32 17
Ceftazidime 4 16 2–16 83
Cefepime 4 16 2–16 67
Amoxicillin-clavulanate 16 16 8–16 —
Piperacillin-tazobactam 8 64 0.5–64 67
Aztreonam 16 16 4–16 17
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LB 11058 MIC of 0.5 g/ml, while the linezolid-resistant Strep-
tococcus oralis had a very low LB 11058 MIC (0.008 g/ml).
Similarly, all quinupristin-dalfopristin-nonsusceptible staphy-
lococci showed LB 11058 MIC results of 2 g/ml.
LB 11058 activity against H. influenzae (MIC90, 0.25 to 0.5
g/ml) was not significantly affected by the production of -lac-
tamase, and it was similar to that of cefepime (MIC90, 0.12 to
0.25 g/ml) and cefuroxime (MIC90, 0.12 to 0.25 g/ml), but
inferior to ceftriaxone (MIC90,0.008 to 0.015 g/ml). Several
other compounds demonstrated potent activity against this
pathogen. LB 11058 (MIC50, 0.03 g/ml) was the most potent
-lactam tested against M. catarrhalis, followed by ceftriaxone
(MIC50, 0.12 g/ml), amoxicillin-clavulanate (MIC50, 0.12 g/
ml), and cefepime (MIC50, 0.5 g/ml) (Table 2).
Against a small number of Enterobacteriaceae strains (31),
the activity of LB 11058 varied by species, but it was generally
(MIC50, 2 g/ml) inferior to that of ceftriaxone (MIC50, 0.25
g/ml), ceftazidime (MIC50, 1 g/ml), or cefepime (MIC50,
0.12 g/ml). The nonfermentative gram-negative bacilli also
showed decreased susceptibility to virtually all compounds
evaluated when compared to the Enterobacteriaceae (Table 2).
DISCUSSION
The past decade has seen a significantly increasing problem
of antimicrobial resistance among gram-positive bacteria, in-
cluding multidrug-resistant staphylococci, penicillin-resistant
streptococci, and vancomycin-resistant enterococci (1, 3, 5, 15,
16, 21, 22). Oxacillin resistance rates are relatively high in
many hospitals worldwide, forcing the use of a glycopeptide or,
more recently, linezolid as empirical therapy for suspected
nosocomial-acquired staphylococcal infections. Moreover,
MRSA has become increasingly described in community-ac-
quired infections in patients who have rarely been hospitalized,
raising the question whether penicillinase-resistant penicillins
(oxacillin, methicillin, nafcillin, etc.) or cephalosporins should
still be used for empirical therapy of community-acquired S.
aureus infections (8, 14).
One of the most remarkable features of LB 11058 was its in
vitro activity against oxacillin-resistant staphylococci. LB 11058
inhibited the growth of all clinical MRSA strains at 1 g/ml,
although other -lactam compounds were not active against
those strains. Oxacillin-resistant CoNS strains (MIC90, 1 g/
ml) were also very susceptible to LB 11058. In this report we
confirmed the potency of LB 11058 against oxacillin-resistant
staphylococci, including multidrug-resistant strains (Cho et al.,
42nd ICAAC). All strains with reduced susceptibility to glyco-
peptides (vancomycin-intermediate or -resistant staphylo-
cocci), linezolid, and quinupristin-dalfopristin showed an LB
11058 MIC of1 g/ml, except for one quinupristin-dalfopris-
tin-nonsusceptible CoNS strain which showed an LB 11058
MIC of 2 g/ml.
S. pneumoniae and H. influenzae are the most common
causes of pyogenic meningitis, community-acquired pneumo-
nia, and otitis media (6). In addition, these pathogens also
represent an important cause of nosocomial pneumonia, espe-
cially when the onset of the disease occurs within 3 to 5 days
after hospital admission (19). Mortality and suppurative com-
plications associated with these infections decrease dramati-
cally with the rapid introduction of appropriate antimicrobial
therapy (22). The clinical impact of antimicrobial resistance
among these pathogens, especially S. pneumoniae, varies ac-
cording to the site of infection, reflecting the degree of drug
penetration to that site and the ability of the host immune
response to clear the infection. Thus, antimicrobial resistance
has led to treatment failure in patients with meningitis and
acute otitis media. The impact of pneumococcal resistance on
treatment of pneumonia has been more difficult to determine,
but high-level -lactam or macrolide resistance has been asso-
ciated with increased morbidity and longer hospital stay (16,
20).
LB 11058 showed excellent in vitro activity against pneumo-
cocci, including multidrug-resistant strains. LB 11058 (MIC50,
0.25 g/ml; MIC90, 0.5 g/ml) was many fold more potent than
ceftriaxone (MIC50, 4 g/ml; MIC90, 32 g/ml) against peni-
cillin-resistant S. pneumoniae (MIC, 2 g/ml). In addition,
LB 11058 was also highly active against H. influenzae, including
-lactamase-producing strains (MIC90, 0.25 g/ml).
In summary, our study showed that LB 11058 is very active
against many clinically important bacterial pathogens, includ-
ing streptococci (-hemolytic, viridans group, and pneumo-
cocci), staphylococci (S. aureus and coagulase negative), H.
influenzae, and M. catarrhalis among others. LB 11058 in vitro
activity against these pathogens was similar to that demon-
strated by other new anti-MRSA cephalosporins (2, 9, 12).
Moreover, LB 11058 was highly active against multidrug-resis-
tant gram-positive pathogens that may cause both community-
TABLE 2—Continued
Organism (no. tested) and antimicrobial agent
MIC (g/ml)
% Susceptible
50% 90% Range
Imipenem 1 8 0.5–8 58
Amikacin 4 32 0.5–16 75
Gentamicin 8 8 2–8 42
Ciprofloxacin 0.5 4 0.03–4 58
Levofloxacin 0.5 4 0.06–4 75
Trimethoprim-sulfamethoxazole 0.5 2 0.5–2 75
a —, no interpretive criteria have been established by the NCCLS.
b Includes Citrobacter freundii (three strains), Enterobacter aerogenes (three strains), Enterobacter cloacae (four strains), E. coli (three strains), Klebsiella oxytoca (two
strains), K. pneumoniae (four strains), Morganella morganii (three strains), Pantoea agglomerans (four strains), Providencia rettgeri (two strains), and Serratia marcescens
(three strains).
c Includes Acinetobacter baumannii (four strains), P. aeruginosa (three strains), Pseudomonas fluorescens (two strains), and Stenotrophomonas maltophilia (three
strains).
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acquired and hospital-acquired infections, especially MRSA
and penicillin-resistant S. pneumoniae. Continued develop-
ment of LB 11058 appears justified.
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